Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Physostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.92 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Physostigmine SCHEMBL15677750 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL9988368 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL4104619 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24044 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL8800695 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24045 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL13930339 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581686 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7581684 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL7587896 | 0.99 | ACHE (0.98) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119510740-A | Therapeutic agent for lipid peroxidation-induced disease and screening method therefor | 扶桑药品工业株式会社 | 2025-02-25 | — | — | CN | claimed |
| US-20220257593-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | VISUS THERAPEUTICS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3980005-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-122080098-A | S-adenosyl homocysteine analogue, S-adenosyl-L-methionine analogue and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-119510740-A | Therapeutic agent for lipid peroxidation-induced disease and screening method therefor | 扶桑药品工业株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20250032440-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2025-01-30 | — | — | US | disclosed |
| EP-4210690-B1 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, HYPEROPIA, ASTIGMATISM, DECREASED STEREOPSIS, AND DECREASED CONTRAST SENSITIVITY | INTRATUS NEVADA INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-12157740-B2 | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | NANTNEURO, LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4210690-A1 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, HYPEROPIA, ASTIGMATISM, DECREASED STEREOPSIS, AND DECREASED CONTRAST SENSITIVITY | Intratus-Nevada, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11490856-B2 | Method and a system for analyzing neuropharmacology of a drug | CITY UNIVERSITY OF HONG KONG (HK) | 2022-11-08 | — | — | US | disclosed |
| CN-110709068-B | Improved sustained release high load pharmaceutical compositions | 路博润先进材料公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2022-10-20 | — | — | US | disclosed |
| CN-107362157-B | Ophthalmic pharmaceutical composition for use in medicine and veterinary medicine | 米拓科技有限公司（卢森堡） | 2022-08-26 | — | — | CN | disclosed |
| US-20220257593-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | VISUS THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11365208-B2 | Silylated derivatives of resveratrol and the use thereof in neurodegenerative, neurological or inflammatory diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2022-06-21 | — | — | US | disclosed |
| EP-3980005-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220079965-A1 | ACYLATED COMPOUNDS FOR THE TREATMENT OF OCULAR PATHOLOGIES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2022-03-17 | — | — | US | disclosed |
| WO-2022055796-A1 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, HYPEROPIA, ASTIGMATISM, DECREASED STEREOPSIS, AND DECREASED CONTRAST SENSITIVITY | Intratus-Nevada, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CNR2, CNR1, DNER | ACHE 406/4885BCHE 676/4885KDM4E 96/4885 |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | ACHE 449/4885BCHE 501/4885KDM4E 111/4885 |
| US-20250032440-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | NLN, PSEN2, PSEN1 | ACHE 28/4885BCHE 237/4885KDM4E 3170/4885 |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | MB, MLEC, NISCH | ACHE 67/4885BCHE 24/4885KDM4E 4113/4885 |
| US-12157740-B2 | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | MAPT, CRH, CRHBP | ACHE 849/4885BCHE 501/4885KDM4E 4414/4885 |
| US-20220079965-A1 | ACYLATED COMPOUNDS FOR THE TREATMENT OF OCULAR PATHOLOGIES | ALDH1A2, CPT1A, CPT2 | ACHE 3861/4885BCHE 3309/4885KDM4E 4076/4885 |
| US-11365208-B2 | Silylated derivatives of resveratrol and the use thereof in neurodegenerative, neurological or inflammatory diseases | SNCA, SIRT1, SIRT5 | ACHE 258/4885BCHE 896/4885KDM4E 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.